NCT05578859View on ClinicalTrials.gov

A Study of the Absorption, Metabolism, and Excretion of [14C]-AMG 510 Following a Single Oral Dose in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 11, 2020

Primary Completion Date

March 24, 2020

Study Completion Date

March 24, 2020

Conditions
Healthy Subjects
Interventions
DRUG

AMG 510

Single oral dose of AMG510.

Trial Locations (1)

53704

Covance Clinical Research Unit, Inc, Madison

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY